Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
ZHENG-RONG LU · CASE WESTERN RESERVE UNIVERSITY · 2023 · $349,785 — The goal of this project is to develop smart dual-targeted lipid ECO/siRNA self-assembly nanoparticles to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat metastatic and drug-resistant triple negative breast cancer (TNBC). Metastasis and drug resistance are the main causes…
Hana Totary-Jain · UNIVERSITY OF SOUTH FLORIDA · 2023 · $486,044 — Atherosclerotic cardiovascular disease (CVD) represents a serious affliction affecting millions globally. Despite recent advances in pharmacological and percutaneous interventions, CVD remains the leading cause of death and disability in the world. One of the main therapeutic challenges facing ather…
Rajagopal Ramesh · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2023 · $343,921 — Effective control of lung cancer continues to remain a clinical challenge resulting in poor five-year survival rate. Currently available therapies while showing promise have had limitations. Therefore, continued efforts for developing new therapeutic agents and systemic treatment modalities are warr…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2023 · $658,627 — ABSTRACT: Cystic fibrosis (CF) is conferred by any of ≥1200 known mutations in the gene encoding the CFTR, an ion transporter protein, but in principle, a single gene therapy agent that delivers expression of functional CFTR could treat. Prior attempts to do so have used adeno-associated viral or li…
Richard Brian Meagher · UNIVERSITY OF GEORGIA · 2023 · $188,750 — DectiSomes are lipid nanoparticles carrying an anti-infective drug and coated with pathogen receptor that targets them to pathogenic cells. DectiSomes reduce the effective dose for inhibition and killing of pathogens by order(s) of magnitude relative to conventional drugs, potentially overcoming the…
JAKE JINKUN CHEN · TUFTS UNIVERSITY BOSTON · 2023 · $588,984 — Patients with type 2 diabetes (T2D) have substantially higher incidence of bone disorders, including as much as a 64% greater risk of fracture as compared to those without T2D. High blood glucose levels adversely alter bone cell functions, causing decreased bone formation and delayed wound healing w…
Bjoern Markus Reinhard · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · 2023 · $206,250 — Summary The structure of important biomolecules is intrinsically dynamic, and there is an important need for optical tools that can probe the structural dynamics of biopolymers at the single molecule level with high temporal resolution and without limitation in maximum observation time. Dynamic mole…
Yizhou Dong · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $626,885 — Immunotherapy treatments such as checkpoint blockade and chimeric antigen receptor T cell therapy have demonstrated the power of the immune system to eradicate metastatic cancer, but the efficacy of immunotherapies in solid tumors remains confined to a minority of patients. A series of interlinked e…
Sheng Tong · UNIVERSITY OF KENTUCKY · 2023 · $229,500 — Summary CRISPR/cas9 gene editing has shown great promise for the treatment of genetic hematologic disorders including sickle cell disease and β-thalassemia. Current therapeutic strategies are primarily focused on ex vivo gene editing of autologous patient-derived hematopoietic stem/progenitor cells …
Marco E Zamora · DREXEL UNIVERSITY · 2023 · $47,694 — Proposal Summary/Abstract Acute respiratory distress syndrome (ARDS) is an acute inflammation of the lungs. It represents 10% of all intensive care unit (ICU) admissions in the United States. Despite decades of research and numerous large clinical trials, there are few treatments for ARDS. This lack…
Omar O Abudayyeh · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $574,001 — Project Summary Despite extraordinary advances in genome engineering, tools for precise and efficient gene correction across all cell types and desired edits remain lacking. Current programmable DNA cleavage tools, such as CRISPR-Cas9, rely on cellular DNA repair mechanisms, which are inefficient an…
Omar Abdel-Wahab · FRED HUTCHINSON CANCER CENTER · 2023 · $748,641 — SUMMARY Many cancers carry recurrent, change-of-function mutations affecting RNA splicing factors, resulting in sequence-specific changes in RNA splicing that promote disease initiation and progression. These “spliceosomal mutations” are the most common class of mutations in myelodysplastic syndrome…
Chunling Dai · POP BIOTECHNOLOGIES, INC · 2023 · $248,855 — Project Summary/Abstract Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to 14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified. Harnessing the immune system to prevent or remove Aβ…
Devanand Sarkar · VIRGINIA COMMONWEALTH UNIVERSITY · 2023 · $29,319 — Summary Nonalcoholic steatohepatitis (NASH), the most common cause of chronic liver disease in the Western world and a major global health problem, leads to cirrhosis and hepatocellular carcinoma (HCC). The lack of an optimum therapy mandates better understanding of the molecular pathogenesis of NAS…
Adam G Berger · HARVARD MEDICAL SCHOOL · 2023 · $52,694 — Project Summary Non-healing ulcers are a common complication of diabetes, resulting in decreased quality of life, elevated rates of amputation, increased risk of mortality, and high healthcare costs. Unfortunately, current treatments remain outdated and inadequate. In diabetes, neuropathy and microv…
ANUP KUMER KUNDU · XAVIER UNIVERSITY OF LOUISIANA · 2023 · $112,500 — ABSTRACT The development of multidrug resistance (MDR) in cancer cells is of grave concern, limiting the efficacy of anticancer agents and, hence, the failure of breast cancer therapy. Clinical research and application revealed that in spite of its potential anticancer effects, doxorubicin is highly…
SATHY VENKAT BALU-IYER · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2023 · $465,506 — Project Summary: Autoimmune conditions, allergies and immunogenicity against therapeutic proteins are caused by unwanted immune responses against proteins. Our long-term goal is to rationally develop an immunotherapy platform using protein delivery strategies to treat these clinical conditions. We o…
Xiaowei Dong · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2023 · $366,352 — Project Summary/Abstract Bioavailability enhancement technologies for insoluble drugs represent incremental progress, but no breakthrough oral drug technologies have been identified in the past three decades. Lipid-based drug delivery systems (LBDDS) are considered as a well-established, very import…
Prabhani Atukorale · UNIVERSITY OF MASSACHUSETTS AMHERST · 2023 · $194,090 — PROJECT SUMMARY Despite their transformative promise, traditional cancer vaccines have had poor clinical responses since vaccine-specific systemic T cells often cannot traffic to immunosuppressed “cold” tumors. Traditional vaccines generate only a lymph node-derived augmentation or “prime” of system…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2023 · $419,679 — Project Summary CRISPR/Cas-based gene editing has ushered in a hopeful era that dreams of new therapies for currently untreatable genetic diseases. Because mutated proteins are produced in specific cells, there is a critical need to develop organ- and cell-specific delivery strategies to realize the…